Apr 09, 2025 / 12:00PM GMT
Frank Mathias - Oxford Biomedica PLC - Chief Executive Officer, Executive Director
So good afternoon to everyone here in London and also good morning to those who are joining us from overseas. Thank you for attending this call today, our analyst briefing for our '24 preliminary results. It's great to see so many people here in the room, known faces, thank you for joining.
But we have also a few people joining virtually. So hello to everyone again. Presenting with me today, we have our Chief Financial Officer, Dr. Lucy Crabtree, who started to join us in September last year and has already made a significant impact during this short period. I'm also pleased to welcome our Chief Business Officer, Dr. Sébastien Ribault. You are known, I believe, well here and a lot of you are familiar with him.
So disclaimer, let's -- before we dive in, let's start with our agenda for today. As you can see, we will start with an overview of the key achievements across the business, highlighting what sets up OXB apart from our peers and how our differentiated pure play CDMO strategy and cell gene therapy
Full Year 2024 Oxford Biomedica PLC Earnings Call Transcript
Apr 09, 2025
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers